RAC1 and cancer: Additionally, knockdown reduced levels of β-catenin and Rac1 proteins as well as downstream target genes, confirming the interaction of DDX3X with the Rac1/β-catenin pathway in cancer progression and indicating a potential therapeutic target for tumors with increased Wnt activity.